Business

Appointment of a Non-Executive Director

Appointment of a Non-Executive Director.

articleAvacta Group PlcAugust 5, 20133/company/avacta-group-plc/news/appointment-of-a-non-executive-director-11
Appointment of a Non-Executive Director

About this update from Avacta Group Plc

[{"type":"text","content":"\n \nRNS Number : 8976K Avacta Group PLC 05 August 2013  \n \n\n \n\n\n\n\nPress Release \n\n\n5 August 2013\n\n\n\n\n \nAvacta Group plc\n(\"Avacta\" or the \"Group\")\nDr Trevor Nicholls joins the Board of Avacta Group plc as a Non-executive Director\nEx-Chief Commercial Officer of Affymetrix Joins Avacta Board\n                             \nAvacta Group plc (AIM: AVCT), a global provider of innovative diagnostic tools, consumables and reagents aimed at reducing the cost of human and animal healthcare, is pleased to announce that Dr Trevor Nicholls has joined the Board as a Non-executive Director with immediate effect.\n \nDr Nicholls has over 30 years of commercial experience building international businesses in the life sciences sector.  As Chief Commercial Officer and Executive Vice President of Affymetrix, Dr Nicholls was responsible for global operations including sales, marketing, product development and manufacturing, overseeing approximately 600 staff across 8 locations worldwide.  In this role he grew product revenue from US$249 million to US$330 million in two years with the launch of a large number of new products including major instrument systems during that period.  \n \nDr Nicholls is currently Chief Executive Officer of the not-for-profit CAB International, an intergovernmental organisation owned by 47 member countries whose mission is to improve lives worldwide by providing information and applying scientific expertise to solve problems in agriculture and the environment.  He is also Non-Executive Chairman of Activiomics Limited, a UK biomarker discovery and drug profiling services business and was founder and CEO of Oxagen, a UK biotech company where he successfully raised approximately £50 million over three venture-backed financing rounds and secured major commercial partnerships.  Prior to that he held senior commercial positions with Amersham International and worked in consultancy with McKinsey.\n \nTrevor brings great experience in commercial and corporate strategy, international sales and marketing and building life sciences businesses. \n \nCommenting on the appointment, Alastair Smith, Chief Executive o...

More updates from Avacta Group Plc